
Hongying Gao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/37427/publications.pdf Version: 2024-02-01



HONCYING GAO

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Nature Chemical Biology, 2021, 17, 567-575. | 8.0 | 76 |
| 2 | Design, synthesis, and biological evaluation of multiple targeting antimalarials. Acta Pharmaceutica Sinica B, 2021, 11, 2900-2913. | 12.0 | 3 |
| 3 | Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. Antiviral Research, 2021, 194, 105161. | 4.1 | 6 |
| 4 | Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs. ACS Medicinal Chemistry Letters, 2020, 11, 1855-1862. | 2.8 | 50 |
| 5 | Global PROTAC Toolbox for Degrading BCR–ABL Overcomes Drug-Resistant Mutants and Adverse Effects. Journal of Medicinal Chemistry, 2020, 63, 8567-8583. | 6.4 | 52 |
| 6 | PROTAC Technology: Opportunities and Challenges. ACS Medicinal Chemistry Letters, 2020, 11, 237-240. | 2.8 | 169 |
| 7 | Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase. Journal of Medicinal Chemistry, 2020, 63, 4908-4928. | 6.4 | 38 |
| 8 | FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice. Protein and Cell, 2020, 11, 534-539. | 11.0 | 24 |
| 9 | Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. Journal of Medicinal Chemistry, 2019, 62, 7575-7582. | 6.4 | 127 |
| 10 | PROTACs: great opportunities for academia and industry. Signal Transduction and Targeted Therapy, 2019, 4, 64. | 17.1 | 367 |
| 11 | Synthesis of Quaternary Carbon-Centered Benzoindolizidinones via Novel Photoredox-Catalyzed Alkene Aminoarylation: Facile Access to Tylophorine and Analogues. CCS Chemistry, 2019, 1, 352-364. | 7.8 | 10 |
| 12 | Developing Equipotent Teixobactin Analogues against Drug-Resistant Bacteria and Discovering a Hydrophobic Interaction between Lipid II and Teixobactin. Journal of Medicinal Chemistry, 2018, 61, 3409-3421. | 6.4 | 35 |
| 13 | PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Research, 2018, 28, 779-781. | 12.0 | 215 |
| 14 | Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 4553-4559. | 3.0 | 13 |